StreetInsider.com News Articles

Form SCHEDULE 13G Virax Biolabs Group Ltd Filed by: ARMISTICE CAPITAL, LLC

Tue, 17 Feb 2026 21:42:00 -0500

si-local-file:///var/storage/secattach/20260217/26016303.html

Form SCHEDULE 13G Virax Biolabs Group Ltd Filed by: ARMISTICE CAPITAL, LLC

Tue, 17 Feb 2026 21:42:00 -0500

si-local-file:///var/storage/secattach/20260217/26016303.html

Form 6-K Virax Biolabs Group Ltd For: Jan 30

Fri, 30 Jan 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260130/25923398.html

Form 6-K Virax Biolabs Group Ltd For: Jan 30

Fri, 30 Jan 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20260130/25923398.html

Virax Biolabs Group (VRAX) PT Lowered to $1 at H.C. Wainwright

Mon, 12 Jan 2026 06:50:39 -0500

(Updated - January 12, 2026 6:50 AM EST)

H.C. Wainwright analyst Yi Chen lowered the price target on Virax Biolabs Group (NASDAQ: VRAX) to $1.00 (from $3.00) while maintaining a Buy rating.

The analyst commented: "Last month, Virax Biolabs provided an update on its clinical progress and its strategic priorities for 2026. As a reminder, the company’s diagnostic candidate, ViraxImmune, targets post-acute infection syndromes (PAIS), including long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-treatment Lyme disease (PTLD). The company’s core focus in 2026 includes: (1) deliver initial data from the UK PAIS study to support UK regulatory submission; (2) initiate a

Virax Biolabs Group (VRAX) PT Lowered to $1 at H.C. Wainwright

Mon, 12 Jan 2026 06:50:39 -0500

(Updated - January 12, 2026 6:50 AM EST)

H.C. Wainwright analyst Yi Chen lowered the price target on Virax Biolabs Group (NASDAQ: VRAX) to $1.00 (from $3.00) while maintaining a Buy rating.

Form 424B3 Virax Biolabs Group Ltd

Wed, 31 Dec 2025 17:00:00 -0500

si-local-file:///var/storage/secattach/20251231/25794883.html

Form 424B3 Virax Biolabs Group Ltd

Wed, 31 Dec 2025 17:00:00 -0500

si-local-file:///var/storage/secattach/20251231/25794883.html

Form EFFECT Virax Biolabs Group Ltd

Wed, 31 Dec 2025 06:04:00 -0500

si-local-file:///var/storage/secattach/20251231/25792477.html

Form EFFECT Virax Biolabs Group Ltd

Wed, 31 Dec 2025 06:04:00 -0500

si-local-file:///var/storage/secattach/20251231/25792477.html

Virax Biolabs Group (VRAX) files for 25.88M share offering by selling stockholders

Thu, 18 Dec 2025 16:08:39 -0500

Virax Biolabs Group (NASDAQ: VRAX) has filed for up to 25,875,000 share offering by selling stockholders.

Virax Biolabs Group (VRAX) files for 25.88M share offering by selling stockholders

Thu, 18 Dec 2025 16:08:39 -0500

Virax Biolabs Group (NASDAQ: VRAX) has filed for up to 25,875,000 share offering by selling stockholders.

Form F-3 Virax Biolabs Group Ltd

Thu, 18 Dec 2025 16:06:00 -0500

si-local-file:///var/storage/secattach/20251218/25759287.html

Form F-3 Virax Biolabs Group Ltd

Thu, 18 Dec 2025 16:06:00 -0500

si-local-file:///var/storage/secattach/20251218/25759287.html

Form D Virax Biolabs Group Ltd

Thu, 18 Dec 2025 10:06:00 -0500

si-local-file:///var/storage/secattach/20251218/25757466.html

Form D Virax Biolabs Group Ltd

Thu, 18 Dec 2025 10:06:00 -0500

si-local-file:///var/storage/secattach/20251218/25757466.html

Form 6-K Virax Biolabs Group Ltd For: Dec 04

Thu, 04 Dec 2025 16:07:00 -0500

si-local-file:///var/storage/secattach/20251204/25701467.html

Form 6-K Virax Biolabs Group Ltd For: Dec 04

Thu, 04 Dec 2025 16:07:00 -0500

si-local-file:///var/storage/secattach/20251204/25701467.html

Virax Biolabs closes $5 million private placement

Thu, 04 Dec 2025 16:05:15 -0500

Virax Biolabs Group Limited (NASDAQ: VRAX) completed a private placement of securities for gross proceeds of $5 million, the biotechnology company announced.

The company sold 12.5 million ordinary shares and preferred investment options to purchase up to 12.5 million ordinary shares at a combined price of $0.3999 per pre-funded warrant and accompanying preferred investment option. The pre-funded warrants have an exercise price of $0.0001 per share and do not expire, while the preferred investment options carry an exercise price of $0.40 per ordinary share and are exercisable for five years.

H.C. Wainwright & Co. served as the exclusive placement agent for the

Virax Biolabs closes $5 million private placement

Thu, 04 Dec 2025 16:05:15 -0500

Virax Biolabs Group Limited (NASDAQ: VRAX) completed a private placement of securities for gross proceeds of $5 million, the biotechnology company announced.

H.C. Wainwright & Co. served as the exclusive placement agent for the

Virax Biolabs closes $5 million private placement

Thu, 04 Dec 2025 16:05:15 -0500

Virax Biolabs Group Limited (NASDAQ: VRAX) completed a private placement of securities for gross proceeds of $5 million, the biotechnology company announced.

H.C. Wainwright & Co. served as the exclusive placement agent for the

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Thu, 04 Dec 2025 16:05:00 -0500

Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships.

LONDON, Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Thu, 04 Dec 2025 16:05:00 -0500

Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships.

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Thu, 04 Dec 2025 16:05:00 -0500

Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships.

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Thu, 04 Dec 2025 16:05:00 -0500

Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships.